Literature, news and videos pertinent to
The Brigitte Lavigne
Research Advocacy Program
(Rare Resistance Mutations)

PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset
By The ASCO Post Staff
December 10, 2023 - Supplement: ESMO Highlights

National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
By The ASCO Post Staff
October 10, 2022 - Supplement: Conference Highlights IASLC 2022

Screening for Lung Cancer with Low Dose Computed Tomography (LDCT)CMS.gov Centers for Medicare & Medicaid Services

INHERIT EGFR - Studying Germline EGFR Mutations (INHERIT)ClinicalTrials.gov

powered by Surfing Waves

The Brigitte Lavigne Research Advocacy Program (Rare Resistance Mutations)
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.

Use our secure Donate Platform

Donate



We also accept PayPal
paypal.me/ICANadvocacy


Guidestar Platinum Seal of Transparency 2021


Federal Tax I.D.: EIN 86-0818253